Cancer treatments

Global Cancer Immunotherapy Market is Forecast to Hit $100 Billion by 2022

Monday, October 14, 2019 - 1:00pm

Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.

Key Points: 
  • Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.
  • An overview of cancer immunotherapy that includes monoclonal antibodies, ADC's, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
  • Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
  • To that end, the Cancer Immunotherapy Market is forecast to hit $100 billion by 2022.

Global Cancer Immunotherapy Market is Forecast to Hit $100 Billion by 2022

Monday, October 14, 2019 - 1:00pm

Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.

Key Points: 
  • Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.
  • An overview of cancer immunotherapy that includes monoclonal antibodies, ADC's, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
  • Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
  • To that end, the Cancer Immunotherapy Market is forecast to hit $100 billion by 2022.

Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Thursday, October 10, 2019 - 1:00pm

We are pleased to advance this tucatinib clinical trial with the vision of improving combination outcomes for patients with HER2-positive metastatic breast cancer who receive T-DM1.

Key Points: 
  • We are pleased to advance this tucatinib clinical trial with the vision of improving combination outcomes for patients with HER2-positive metastatic breast cancer who receive T-DM1.
  • Tucatinib has been granted orphan drug designation by the FDA for the treatment of breast cancer patients with brain metastases.
  • Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer.
  • Moulder, S. et al., Phase 1 Trial of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer.

City of Hope Is Enrolling Patients in First of Its Kind Clinical Trial for Brain Tumor Patients

Wednesday, October 9, 2019 - 5:00pm

The trial will deliver CAR T cells that target IL13R2 locally to the brain, by direct injection to the tumor site and through infusion into the ventricular system.

Key Points: 
  • The trial will deliver CAR T cells that target IL13R2 locally to the brain, by direct injection to the tumor site and through infusion into the ventricular system.
  • City of Hope was the first to use this type of delivery for glioblastoma patients receiving CAR T treatment, as well as the first to investigate CAR T cells targeting IL13R2.
  • Mustang Bio Inc. (NASDAQ: MBIO) is the exclusive licensee of City of Hope patents covering its IL13R2-specific CAR T cell therapy.
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy .

A Pancreatic and Colorectal Cancer Trial Initiated to Address the Needs of Patients With Immune Checkpoint Inhibitor (ICI)-Resistant Disease by Combining Debiopharm's Debio 1143 IAP Antagonist With Keytruda®

Wednesday, October 9, 2019 - 1:33pm

The CATRIPCA study focuses on two cancer patient populations with conditions that are intrinsically resistant to Immune Checkpoint Inhibitors (ICI).

Key Points: 
  • The CATRIPCA study focuses on two cancer patient populations with conditions that are intrinsically resistant to Immune Checkpoint Inhibitors (ICI).
  • More specifically, the trial will recruit patients without other available therapeutic options in Non-microsatellite instability (non-MSI)-high colorectal cancer (CRC) and pancreatic ductal adenocarcinoma cancer (PDAC).
  • As preclinical models have demonstrated synergy between Debio 1143 and immunotherapy, the compound is expected to offer an immune-sensitizing effect.
  • Debio 1143 is an IAP antagonist with a dual mode of action, promoting programmed cell death and fostering anti-tumor immunity.

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

Wednesday, October 9, 2019 - 12:00pm

Oncologie is collaborating with MSD in this clinical study to evaluate the combination of bavituximab and KEYTRUDA in patients with advanced gastric or gastroesophageal cancer.

Key Points: 
  • Oncologie is collaborating with MSD in this clinical study to evaluate the combination of bavituximab and KEYTRUDA in patients with advanced gastric or gastroesophageal cancer.
  • The rationale to support this study was based on a previously reported retrospective analysis from over 90 patients who were enrolled in a Phase 3 lung cancer study, which demonstrated activity when Bavituximab was given prior to a PD-1 inhibitor.
  • "This Phase 2 study is intended to further evaluate the antitumor activity and safety of bavituximab plus pembrolizumab in a gastric cancer population.
  • Headquartered in Boston, Massachusetts and Shanghai, China, Oncologie is working with global partners to acquire and develop innovative drugs for cancer patients around the world.

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

Tuesday, October 8, 2019 - 2:50pm

The study showed that AN0025 was well tolerated in combination with chemoradiation as well as to radiotherapy followed by consolidation chemotherapy.

Key Points: 
  • The study showed that AN0025 was well tolerated in combination with chemoradiation as well as to radiotherapy followed by consolidation chemotherapy.
  • The preliminary efficacy demonstrated encouraging clinical results in locally advanced rectal cancer.
  • There is a tremendous need for new treatment strategies in rectal cancer, especially in patients with high-risk of relapse enrolled in this study.
  • For further information about Adlai Nortye, please visit: http://www.adlainortye.com/en.php
    View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005612/en/

Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Tuesday, October 8, 2019 - 2:00pm

Enrolling 100 patients in our pancreatic cancer clinical trial is an important milestone for Rafael, said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals.

Key Points: 
  • Enrolling 100 patients in our pancreatic cancer clinical trial is an important milestone for Rafael, said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals.
  • Pancreatic cancer is one of the deadliest cancers in the world and patients with metastatic pancreatic cancer, specifically, have a very low five-year survival rate of 3%.
  • Philip A. Philip, M.D., Professor of Oncology at the Barbara Ann Karmanos Cancer Institute at Wayne State University , is the principal investigator on Rafaels Phase 3 clinical trial for patients with metastatic pancreatic cancer.
  • Pancreatic cancer has remained a difficult disease to treat, and I am hopeful that the data from this trial will demonstrate devimistats potential in treating metastatic pancreatic cancer.

Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019

Tuesday, October 8, 2019 - 1:00pm

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2019 financial results on Tuesday, October 29, 2019 after the close of financial markets.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2019 financial results on Tuesday, October 29, 2019 after the close of financial markets.
  • Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
  • ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.
  • Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology.

Triumvira Announces Grant of T Cell Antigen Coupler (TAC) Technology Patent by U.S. Patent and Trademark Office

Tuesday, October 8, 2019 - 1:00pm

The allowed composition-of-matter claims describe multiple structures used in TAC constructs providing broad protection of the companys TAC platform.

Key Points: 
  • The allowed composition-of-matter claims describe multiple structures used in TAC constructs providing broad protection of the companys TAC platform.
  • Triumvira is developing a proprietary T Cell Antigen Coupler (TAC) technology platform which is biologically distinct from CAR-T.
  • The first of the companys pipeline product candidates, TAC01-CD19, is a novel T cell therapy product targeting CD19 for use in B-cell malignancies.
  • The product comprises patient-derived T cells that have been genetically engineered to express the CD19 T cell Antigen Coupler (TAC).